SPLASH BEVERAGE GROUP, INC. (SBEV) Form 8-K — Jul 6, 2026
Splash Beverage Group entered into an Exclusive License Agreement with Argent Biopharma Limited to acquire worldwide rights to CannEpil, a proprietary cannabinoid formulation for the treatment of drug-resistant epilepsy and seizure disorders. To facilitate the transaction, the company issued 5,500 shares of Series D Convertible Preferred Stock with a total stated value of $5.5 million to Mercer Street Global Opportunity Fund, which in turn cancelled approximately $5.5 million in debt held by Argent.
Key figures
- Royalty rate
- 15%
- Debt cancelled
- 5521432
- Series d shares
- 5500
- Sales bonus amount
- 1000000
- Cm capital investment
- 1000000
- Sales bonus threshold
- 5000000
- Series d stated value
- 5500000
- Series d conversion price
- 0.25
Price after filing
Close on the filing date to close N calendar days later (from $0.83). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.